drug

Intranasal Oxytocin Spray

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of North Carolina, Chapel Hill
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
NCT01394471Phase 1Completed

KOLs & investigators

2
David L. Penn, PhDKOL score 5
Cort A Pedersen, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
University of North Carolina, Chapel Hill
company
trial
Oxytocin Treatment of Social Cognitive and Functional Deficits in Schizophrenia
PHASE1
trial
indication
Schizophrenia
indication
Paranoid Disorders
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
David L. Penn, PhD
KOL score 5
person
Cort A Pedersen, MD
KOL score —
person